Arcutis Biotherapeutics, Inc.
ARQT
$20.69
-$0.55-2.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 65.08% | 83.83% | 121.69% | 164.13% | 196.01% |
| Total Other Revenue | -- | 0.00% | -- | -- | -92.86% |
| Total Revenue | 60.07% | 81.48% | 121.69% | 164.13% | 32.84% |
| Cost of Revenue | 10.80% | 69.27% | 57.82% | 116.28% | 171.19% |
| Gross Profit | 67.70% | 82.79% | 130.65% | 170.18% | 23.11% |
| SG&A Expenses | 15.74% | 37.10% | 6.10% | 18.90% | 16.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.68% | 40.67% | 8.20% | 18.76% | 11.31% |
| Operating Income | 62.95% | 340.92% | 121.82% | 70.82% | 22.43% |
| Income Before Tax | 54.80% | 270.71% | 118.03% | 70.30% | 29.31% |
| Income Tax Expenses | -66.67% | 45.51% | -- | -- | -13.89% |
| Earnings from Continuing Operations | 54.93% | 261.24% | 117.84% | 69.64% | 29.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.93% | 261.24% | 117.84% | 69.64% | 29.17% |
| EBIT | 62.95% | 340.92% | 121.82% | 70.82% | 22.43% |
| EBITDA | 60.43% | 358.92% | 124.05% | 71.63% | 31.07% |
| EPS Basic | 56.09% | 256.94% | 117.38% | 70.48% | 37.60% |
| Normalized Basic EPS | 55.98% | 266.22% | 117.57% | 71.12% | 37.71% |
| EPS Diluted | 56.09% | 243.09% | 117.38% | 70.48% | 37.60% |
| Normalized Diluted EPS | 55.98% | 257.06% | 116.85% | 71.12% | 37.71% |
| Average Basic Shares Outstanding | 2.64% | 2.67% | 2.67% | 2.85% | 13.50% |
| Average Diluted Shares Outstanding | 2.64% | 8.58% | 6.90% | 2.85% | 13.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |